It was concluded that molnupiravir decreases the clinical symptoms and rapid recovery from COVID-19 infection (proved by negative RT–PCR) [ 84 ]
Study design1
3% among participants treated with 800 mg of The phase 3 component of MOVe-OUT, a phase 2–3, double-blind, parallel-group, randomized, placebo-controlled trial evaluating the safety and efficacy of molnupiravir in nonhospitalized adults Randomization used a 2:1 allocation ratio so that, within each cohort, 4 participants were randomly assigned to receive molnupiravir plus standard-of-care and 2 participants (controls) standard-of-care alone
Periodic samples were collected for virologic analysis
MOVe-OUT (protocol MK-4482-002) is an ongoing global phase 2/3, randomized, placebo-controlled, double-blind study that was initiated in October 2020 and evaluates the safety and efcacy of molnupiravir in nonhospitalized
It should be recalled that an interim analysis (n = 775) of MOVe-OUT study that
Molnupiravir (MK-4482) is an oral prodrug of the antiviral ribonucleoside analog, N-hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)
About MSD Efforts to randomized, double-blind, placebo-controlled Phase 3 study, which is evaluating the efficacy and safety of molnupiravir in preventing the spread of COVID-19 within
The oral antiviral molnupiravir cuts the risk of hospitalization and death from COVID-19 by 50% in people who have mild to moderate forms of the disease
Objectives: AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments
For adults over the age of 18, the current recommended dosage is 800 mg (four 200-mg
1056/EVIDoa2100043